50 results
6-K
EX-99.3
IFRX
InflaRx N.V.
1 Nov 23
Current report (foreign)
8:04am
responsibility for the content of this work lies with InflaRx.
Contacts:
InflaRx N.V.
MC Services AG
Email: IR@inflarx.de
Katja Arnold, Laurie Doyle
6-K
EX-99.1
IFRX
InflaRx N.V.
30 Aug 23
Current report (foreign)
8:00am
work described herein is partly funded by the German Federal Government through grant number 16LW0113 (VILO-COVID). All responsibility for the content
6-K
EX-99.2
IFRX
InflaRx N.V.
10 Aug 23
Report of Foreign Private Issuer
8:00am
responsibility for medical affairs. In addition, we are building the necessary infrastructure, including IT systems, supply chain, financial reporting systems
6-K
EX-99.3
IFRX
InflaRx N.V.
10 Aug 23
Report of Foreign Private Issuer
8:00am
through grant number 16LW0113 (VILO-COVID). All responsibility for the content of this work lies with InflaRx.
Contacts:
InflaRx N.V.
MC Services AG
424B5
5bu8u6j
12 Jul 23
Prospectus supplement for primary offering
12:00am
F-3
EX-4.2
bsnq uiy4
30 Jun 23
Shelf registration (foreign)
4:06pm
F-3
EX-5.2
9gp4o ly2jllb4to5i
30 Jun 23
Shelf registration (foreign)
4:06pm
F-3
EX-4.3
0drcr8s5s 1yfx6ytpv
30 Jun 23
Shelf registration (foreign)
4:06pm
F-3
zv1c1x s3
30 Jun 23
Shelf registration (foreign)
4:06pm
6-K
EX-99.1
65qman24 mf9ha9ahlk
21 Jun 23
InflaRx Announces Commercial Launch of Gohibic (vilobelimab) in the U.S. for the Treatment of Critically Ill COVID-19 Patients
8:30am
6-K
EX-99.3
mo1s5ydk
11 May 23
Current report (foreign)
8:00am
6-K
EX-1.1
qw4p8ku7lne2mmg cr86
13 Apr 23
Current report (foreign)
4:01pm
424B5
2n847htreyb6 x3
13 Apr 23
Prospectus supplement for primary offering
8:48am
424B5
8gkvke1rjxlxernr13jd
11 Apr 23
Prospectus supplement for primary offering
4:11pm
6-K
EX-99.1
ijs bcsud2
4 Apr 23
InflaRx Receives FDA Emergency Use Authorization for Gohibic (vilobelimab) for Treatment of Critically Ill COVID-19 Patients
4:50pm
6-K
EX-99.1
pk8 47p0b9e2a7ft5c
21 Dec 22
Current report (foreign)
7:45am
6-K
EX-99.4
rq0iu qr1rj178v
9 Nov 22
Current report (foreign)
7:52am
6-K
EX-99.1
a47x4bsggph8au
29 Sep 22
InflaRx Submits Request for Emergency Use Authorization to US FDA for Vilobelimab for Treatment of Critically Ill COVID-19 Patients
8:00am
6-K
EX-99.1
t8kin614172lejx
8 Sep 22
InflaRx Announces Vilobelimab Phase III Results in Critically Ill COVID-19 Patients Published in The Lancet Respiratory Medicine
8:00am